Navigation Links
Nexavar Significantly Extends Survival of Liver Cancer Patients

CHICAGO, Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc. today announced that Nexavar(R) (sorafenib) tablets significantly extended overall survival in patients with hepatocellular carcinoma (HCC), or primary liver cancer versus those taking placebo by 44%. Results were presented at the 43rd annual meeting of the American Society of Clinical Oncology (ASCO).

The international, Phase 3, placebo-controlled Sorafenib HCC Assessment Randomized Protocol (SHARP) Trial randomized and evaluated 602 liver cancer patients who had no prior systemic therapy at sites in the Americas, Europe, and Australia/New Zealand. The primary objective of the study was to compare overall survival in patients administered Nexavar versus those administered placebo.

Median overall survival was 10.7 months in Nexavar-treated patients compared to 7.9 months in those taking placebo."Because there are no therapies that significantly improve survival for the thousands of patients with liver cancer, these findings demonstrate the compelling study results of Nexavar as the new reference standard of care for the first-line treatment of HCC," said Dr. Josep M. Llovet, co-principal investigator and Professor of Research, Barcelona Clinic Liver Cancer (BCLC) Group, IDIBAPS, Liver Unit, Hospital Clinic Barcelona; Director of Research, HCC Program, Associate Professor of Medicine, Mount Sinai School of Medicine, New York.Bayer and Onyx halted the SHARP trial in February 2007 when an independent data monitoring committee determined in a pre-scheduled analysis that the overall survival endpoint had been met.

There were no significant differences in serious adverse event rates between the Nexavar and placebo-treated groups, with the most commonly observed serious adverse events in patients receiving Nexavar being diarrhea and hand-foot-skin reaction. Based on the strength of the data, the companies are now in the process of preparing applications to the U.S.

Food and Drug Administration (FDA) and European health authorities for a supplemental indication for Nexavar in treatment of patients with liver cancer."Although much progress has been made in cancer research, the number of lives lost to liver cancer is increasing," said Dr. Jordi Bruix, co-principal investigator and Director of the Barcelona Clinic Liver Cancer (BCLC) Group; Senior Consultant, Liver Unit, Hospital Clinic of Barcelona.

"For that reason, these results represent an unprecedented achievement and Nexavar could become the first widely-approved new therapy for this difficult to treat cancer."Hepatocellular carcinoma is the most common form of liver cancer and is responsible for about 90 percent of the primary malignant liver tumors in adults.


'"/>




Related medicine news :

1. Violence at Work Significantly Boosts Clinical Depression Risk
2. Computer-Driven System Reduces Patient Mechanical Ventilation Time Significantly
3. New Study: Pine Bark Significantly Reduces Endometriosis
4. STIs Significantly Increase Risk of Drug-resistant HIV Transmission
5. Masimo SET Pulse Oximetry Technology Significantly Reduce the Risk of ROP
6. Intensity of Rheumatoid Arthritis Significantly Reduced by Pregnancy
7. Irish Medicines Board Extends Paracetamol Recall To All Batches
8. Treatment Extends Survival in Mouse Model of Spinal Muscular Atrophy
9. Caloric Restriction in Non-obese People Extends Life Span
10. Vitamin Extends Life in Yeast, Dartmouth Medical School Researchers Find
11. Vitamin Extends Life in Yeast, Dartmouth Medical School Researchers Find
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the digital ... B led by Canvas Ventures . Other investors include Nokia Growth Partners (NGP) ... platform to serve more consumers who are managing chronic conditions or simply ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... from offices headquartered in Jefferson County, is announcing the launch of a charity ... , The number of homeless women and children in Birmingham has grown steadily ...
(Date:12/8/2016)... St. Louis, MS (PRWEB) , ... December 08, 2016 , ... ... offices that serve commercial and residential clients in and around the Hancock County area, ... support for the Hancock County Food Pantry. , The Hancock County Food Pantry has ...
(Date:12/7/2016)... KING OF PRUSSIA, PA (PRWEB) , ... December 07, 2016 , ... ... of clinical trials with the announcement that it is one of the early adopters ... EU-U.S. Privacy Shield Framework is designed to provide companies on both sides of the ...
(Date:12/7/2016)... ... ... Kenall Manufacturing, a leader in sealed healthcare lighting for more than 30 ... sealed, LED luminaire that meets the needs of everyone in the patient room by ... , A 2’ x 4’ model features four modes: reading, ambient, standard and high ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)...  Hanson Research, an innovative leader in the ... testing instruments for the pharmaceutical industry, announced today ... ("Teledyne"). The move is designed to deepen investments ... as well as expand resources for further market ... services. Logo - http://photos.prnewswire.com/prnh/20161208/446988LOGO ...
(Date:12/8/2016)... Dec. 8, 2016 Augmedix, the nation,s ... it has closed a $23 million strategic round ... OrbiMed. The company seeks to rehumanize the physician ... on mandated EHR documentation. The Augmedix core offering ... frees doctors from 3 hours of mandated charting ...
(Date:12/8/2016)... N.J., Dec. 8, 2016 CANTEL MEDICAL CORP. (NYSE: ... of $18,800,000, or $0.45 per diluted share, on a 22.1% ... quarter ended October 31, 2016. This compares with net income ... $153,779,000 for the first quarter ended October 31, 2015. ... quarter ended October 31, 2016 to $21,323,000, or $0.51 per ...
Breaking Medicine Technology: